Over the years Zambon has earned a strong reputation for high quality products and services. Zambon is well-established in three therapeutic areas respiratory, pain and women’s health and is strongly committed to the entry in the CSN space.
In 2013, Zambon started building a product portfolio for rare diseases with the acquisition of Profile Pharma, a company specialized in cystic fibrosis.
At the end of 2015, Zambon entered the central nervous system (CNS) therapeutic area with safinamide, the first new drug for Parkinson's disease to be approved in 10 years. The launch of the molecule marked the beginning of a new era and the challenge going forward is to continue to work on this important therapeutic area as well as identifying other rare disease opportunities.
Zambon wants to provide its own innovative interpretation of the role that drug companies as well as healthcare operators will have to play in the future: putting the patients at the centre and listening carefully to their needs providing integrated products, services and solutions.